Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 15/20 | 0.78 |
| ▸ | ICOSLG | O75144 | 11/20 | 0.78 |
| ▸ | ICOS | Q9Y6W8 | 11/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | IKBKB | O14920 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.77 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253081 | 0.90 | CHUK (0.75) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13376959 | 0.89 | CHUK (0.89) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL13377038 | 0.88 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL29359984 | 0.87 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL1420453 | 0.87 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL14253078 | 0.86 | CHUK (0.83) | CHUKICOSLGICOSMEN1IKBKB | |
| Hydrochloric Acid SCHEMBL12471533 | 0.86 | CHUK (0.98) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL14253005 | 0.86 | CHUK (0.83) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL14253037 | 0.86 | CHUK (1.00) | CHUKICOSLGICOSMEN1IKBKB | |
| SCHEMBL2768231 | 0.85 | CHUK (0.78) | CHUKICOSLGICOSMEN1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268477-B1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-21 | — | — | EP | disclosed |
| WO-2008133884-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-11-06 | — | — | WO | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7348336-B2 | Substituted β-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20060166978-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-07-27 | — | — | US | disclosed |
| US-7026331-B2 | Substituted beta-carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040110759-A1 | Substituted beta carbolines | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-06-10 | — | — | US | disclosed |
| US-6627637-B2 | I kappa B kinase inhibitors for treating various disorders including arthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-30 | — | — | US | disclosed |
| EP-1268477-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-20020099068-A1 | Substituted beta carbolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| EP-1209158-A1 | Substituted beta-carbolines | Aventis Pharma Deutschland GmbH (DE) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001068648-A1 | SUBSTITUTED BETA-CARBOLINES WITH IKB-KINASE INHIBITING ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110759-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | CHUK 52/4885ICOSLG 4842/4885ICOS 4455/4885 |
| US-20020099068-A1 | Substituted beta carbolines | CSNK1A1, CSNK2A1, CSNK2B | CHUK 52/4885ICOSLG 4842/4885ICOS 4455/4885 |
| US-20060166978-A1 | Substituted beta carbolines | NFKBIA, RELA, IKBKG | CHUK 8/4885ICOSLG 4589/4885ICOS 2392/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | CHUK 4/4885ICOSLG 3193/4885ICOS 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.